Michael G. Collins
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Michael G. Collins has a total of 218 co-authors. Here are the top co-authors by number of shared publications:
Philip A. Clayton
Transplant Epidemiology Group, Australia and New Zealand Dialysis and Transplant Registry, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia
7 shared publicationsCarmel M. Hawley
Australasian Kidney Trials Network, The University of Queensland, Brisbane, Australia
6 shared publicationsElaine M. Pascoe
Australasian Kidney Trials Network, The University of Queensland, Brisbane, Australia
6 shared publicationsDavid W. Johnson
Australasian Kidney Trials Network, The University of Queensland, Brisbane, Australia
4 shared publicationsMagid A. Fahim
Australasian Kidney Trials Network, The University of Queensland, Brisbane, Australia
4 shared publicationsSteven J. Chadban
Department of Renal Medicine, Kidney Centre, Royal Prince Alfred Hospital, Sydney, Australia
4 shared publications
Latest Publications
- 26 May 2026
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 37 (8) , 1802-1805
When Hierarchical Composite End Points Do Not Behave as Expected
- 26 May 2026
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 37 (8) , 1802-1805
When Hierarchical Composite End Points Do Not Behave as Expected
- 5 December 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21 (1) , 9-11
“See You in the Morning?”—Can Hypothermic Machine Perfusion Allow Longer Ischemic Times without Compromising Transplant Outcomes?
- 5 December 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21 (1) , 9-11
“See You in the Morning?”—Can Hypothermic Machine Perfusion Allow Longer Ischemic Times without Compromising Transplant Outcomes?
- 7 March 2025
- Published by Elsevier in Kidney International Reports
- Vol. 10 (5) , 1605-1606
Corrigendum to “Outcomes of Living Kidney Donors Following Donor Nephrectomy in Aotearoa New Zealand” [Volume 10, Issue 3, March 2025, Pages 762-771]
- 7 March 2025
- Published by Elsevier in Kidney International Reports
- Vol. 10 (5) , 1605-1606
Corrigendum to “Outcomes of Living Kidney Donors Following Donor Nephrectomy in Aotearoa New Zealand” [Volume 10, Issue 3, March 2025, Pages 762-771]
- Open Access
- 13 December 2024
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 11 (1) , e1687
Balanced Electrolyte Solutions Versus 0.9% Saline for Kidney Transplantation: An Updated Systematic Review and Meta-analysis
Background.: Perioperative intravenous fluids are administered to kidney transplant recipients to maintain hemodynamic stability and graft perfusion; however, the ideal fluid remains uncertain. Although 0.9% saline (saline) is commonly used, its high chloride content causes hyperchloremic metabolic acidosis and may increase the risks of delayed graft function (DGF) and hyperkalemia. Balanced electrolyte solutions (BES) have a more physiological chloride concentration and may reduce these risks. Previous meta-analyses found insufficient evidence to compare BES with saline for these outcomes; however, new studies have recently been published. In this updated review, we compared the effects of BES with saline on the risk of DGF and hyperkalemia in kidney transplantation. Methods.: MEDLINE, Embase, and CENTRAL were searched for randomized controlled trials comparing BES with saline in kidney transplantation. The primary outcomes were DGF and hyperkalemia. Eligible studies were assessed for risk of bias and data were pooled for analysis. The Grading of Recommendations Assessment, Development, and Evaluation framework was used to assess the quality of evidence. Results.: Ten studies involving 1532 participants were included. The quality of evidence was high for deceased donor transplantation and very low for living donor transplantation. The relative risk (RR) of DGF associated with BES compared with saline was 0.83 (95% confidence interval [CI], 0.71-0.96; P = 0.01) in deceased donor transplantation. There was no difference in DGF in living donor transplantation (RR 0.79; 95% CI, 0.26-2.41; P = 0.68). There was no difference in hyperkalemia between groups (RR 0.87; 95% CI, 0.59-1.27; P = 0.46). Conclusions.: Compared with saline, BES reduces the risk of DGF in deceased donor kidney transplantation without increasing hyperkalemia.
- 13 December 2024
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 11 (1) , e1687
Open AccessBalanced Electrolyte Solutions Versus 0.9% Saline for Kidney Transplantation: An Updated Systematic Review and Meta-analysis
Background.: Perioperative intravenous fluids are administered to kidney transplant recipients to maintain hemodynamic stability and graft perfusion; however, the ideal fluid remains uncertain. Although 0.9% saline (saline) is commonly used, its high chloride content causes hyperchloremic metabolic acidosis and may increase the risks of delayed graft function (DGF) and hyperkalemia. Balanced electrolyte solutions (BES) have a more physiological chloride concentration and may reduce these risks. Previous meta-analyses found insufficient evidence to compare BES with saline for these outcomes; however, new studies have recently been published. In this updated review, we compared the effects of BES with saline on the risk of DGF and hyperkalemia in kidney transplantation. Methods.: MEDLINE, Embase, and CENTRAL were searched for randomized controlled trials comparing BES with saline in kidney transplantation. The primary outcomes were DGF and hyperkalemia. Eligible studies were assessed for risk of bias and data were pooled for analysis. The Grading of Recommendations Assessment, Development, and Evaluation framework was used to assess the quality of evidence. Results.: Ten studies involving 1532 participants were included. The quality of evidence was high for deceased donor transplantation and very low for living donor transplantation. The relative risk (RR) of DGF associated with BES compared with saline was 0.83 (95% confidence interval [CI], 0.71-0.96; P = 0.01) in deceased donor transplantation. There was no difference in DGF in living donor transplantation (RR 0.79; 95% CI, 0.26-2.41; P = 0.68). There was no difference in hyperkalemia between groups (RR 0.87; 95% CI, 0.59-1.27; P = 0.46). Conclusions.: Compared with saline, BES reduces the risk of DGF in deceased donor kidney transplantation without increasing hyperkalemia.
- Open Access
- 4 December 2024
- Published by Elsevier in Kidney International Reports
- Vol. 10 (3) , 762-771
Outcomes of Living Kidney Donors Following Donor Nephrectomy in Aotearoa New Zealand
- 4 December 2024
- Published by Elsevier in Kidney International Reports
- Vol. 10 (3) , 762-771
Open AccessOutcomes of Living Kidney Donors Following Donor Nephrectomy in Aotearoa New Zealand
- Open Access
- 30 September 2024
- Published by Wiley in Nephrology
- Vol. 29 (12) , 930-940
Defining causes of death‐censored kidney allograft failure: A 5‐year multicentre ANZDATA and clinical cross‐sectional study
Aim: Determining specific causes of allograft failure allows a focus on understanding and treating these conditions. Previous studies highlight chronic antibody‐mediated rejection as a leading cause of late allograft failure. We sought to define causes of allograft failure in a large cohort of kidney transplant recipients across multiple centres in Australia and New Zealand, including cases previously attributed to chronic allograft nephropathy (CAN).Methods: All death‐censored allograft failures at 9 participating centres between 1 January 2014 to 31 December 2018 were included. Available clinical and biopsy data were reviewed and the “most likely” cause assigned.Results: There were 642 death‐censored allograft failures in the study period. Of these, 495 (77.1%) had an informative biopsy performed a median of 13.4 months (IQR 2.5–39.1 months) prior to allograft failure. Rejection of any type was the leading cause of allograft failure (47.5%), comprised chiefly of chronic antibody‐mediated rejection (37.4%) and chronic T‐cell mediated rejection (6.4%). Other leading causes were undifferentiated interstitial fibrosis and tubular atrophy (10.8%), late medical and surgical complications (8.1%) and recurrent or de novo glomerulonephritis (7.0%). Polyoma viral nephropathy and calcineurin inhibitor toxicity each contributed to n = 419, 65.3%) had a similar distribution to the overall cohort, with 43.9% attributed to chronic antibody‐mediated rejection.Conclusion: To prolong allograft survival, improved strategies are needed to curtail alloimmune responses. Greater understanding of the causes of undifferentiated interstitial fibrosis and tubular atrophy and potential treatments would also be of considerable benefit.
- 30 September 2024
- Published by Wiley in Nephrology
- Vol. 29 (12) , 930-940
Open AccessDefining causes of death‐censored kidney allograft failure: A 5‐year multicentre ANZDATA and clinical cross‐sectional study
Aim: Determining specific causes of allograft failure allows a focus on understanding and treating these conditions. Previous studies highlight chronic antibody‐mediated rejection as a leading cause of late allograft failure. We sought to define causes of allograft failure in a large cohort of kidney transplant recipients across multiple centres in Australia and New Zealand, including cases previously attributed to chronic allograft nephropathy (CAN).Methods: All death‐censored allograft failures at 9 participating centres between 1 January 2014 to 31 December 2018 were included. Available clinical and biopsy data were reviewed and the “most likely” cause assigned.Results: There were 642 death‐censored allograft failures in the study period. Of these, 495 (77.1%) had an informative biopsy performed a median of 13.4 months (IQR 2.5–39.1 months) prior to allograft failure. Rejection of any type was the leading cause of allograft failure (47.5%), comprised chiefly of chronic antibody‐mediated rejection (37.4%) and chronic T‐cell mediated rejection (6.4%). Other leading causes were undifferentiated interstitial fibrosis and tubular atrophy (10.8%), late medical and surgical complications (8.1%) and recurrent or de novo glomerulonephritis (7.0%). Polyoma viral nephropathy and calcineurin inhibitor toxicity each contributed to n = 419, 65.3%) had a similar distribution to the overall cohort, with 43.9% attributed to chronic antibody‐mediated rejection.Conclusion: To prolong allograft survival, improved strategies are needed to curtail alloimmune responses. Greater understanding of the causes of undifferentiated interstitial fibrosis and tubular atrophy and potential treatments would also be of considerable benefit.
- 2 July 2024
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 35 (9) , 1274-1277
Nephrology Clinical Trials in Learning Health Systems
- 2 July 2024
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 35 (9) , 1274-1277
Nephrology Clinical Trials in Learning Health Systems
- 21 January 2024
- Published by Elsevier in Kidney International
- Vol. 105 (2) , 247-250
Choosing fluids to reduce the risks of acute electrolyte disturbances in children after a kidney transplant
- 21 January 2024
- Published by Elsevier in Kidney International
- Vol. 105 (2) , 247-250
Choosing fluids to reduce the risks of acute electrolyte disturbances in children after a kidney transplant
- Open Access
- 3 July 2023
- Published by Elsevier in Fertility and Sterility
- Vol. 120 (1) , e57
NEW CRYOSTORAGE LABWARE DEVELOPED FOR THE EMBRYOLOGY LABORATORY SIGNIFICANTLY EXTENDS THE RESPONSE TIME IN CASES OF TEMPERATURE EXCURSIONS WHILE HANDLING CRYOPRESERVED SPECIMENS AT AMBIENT CONDITIONS COMPARED TO TRADITIONAL CRYOSTORAGE CANES AND GOBLETS
- 3 July 2023
- Published by Elsevier in Fertility and Sterility
- Vol. 120 (1) , e57
Open AccessNEW CRYOSTORAGE LABWARE DEVELOPED FOR THE EMBRYOLOGY LABORATORY SIGNIFICANTLY EXTENDS THE RESPONSE TIME IN CASES OF TEMPERATURE EXCURSIONS WHILE HANDLING CRYOPRESERVED SPECIMENS AT AMBIENT CONDITIONS COMPARED TO TRADITIONAL CRYOSTORAGE CANES AND GOBLETS
- Top Cited Papers
- 18 June 2023
- Published by Elsevier in The Lancet
- Vol. 402 (10396) , 105-117
Balanced crystalloid solution versus saline in deceased donor kidney transplantation (BEST-Fluids): a pragmatic, double-blind, randomised, controlled trial
- 18 June 2023
- Published by Elsevier in The Lancet
- Vol. 402 (10396) , 105-117
Top Cited PapersBalanced crystalloid solution versus saline in deceased donor kidney transplantation (BEST-Fluids): a pragmatic, double-blind, randomised, controlled trial